Cargando…
Safety and efficacy of Nasya/Prevalin in reducing symptoms of allergic rhinitis
BACKGROUND: Nasya/Prevalin is a natural, drug-free nasal spray for treatment and prevention of allergic rhinitis. Because of its thixotropic property, it forms a barrier on the nasal mucosa, preventing allergen contact. This study assesses the clinical efficacy and safety of Nasya/Prevalin in a nasa...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235399/ https://www.ncbi.nlm.nih.gov/pubmed/24279907 http://dx.doi.org/10.1111/crj.12080 |
_version_ | 1782345020562472960 |
---|---|
author | Stoelzel, Katharina Bothe, Gordana Chong, Pee Win Lenarz, Minoo |
author_facet | Stoelzel, Katharina Bothe, Gordana Chong, Pee Win Lenarz, Minoo |
author_sort | Stoelzel, Katharina |
collection | PubMed |
description | BACKGROUND: Nasya/Prevalin is a natural, drug-free nasal spray for treatment and prevention of allergic rhinitis. Because of its thixotropic property, it forms a barrier on the nasal mucosa, preventing allergen contact. This study assesses the clinical efficacy and safety of Nasya/Prevalin in a nasal provocation test with house dust mite allergens. METHODOLOGY/PRINCIPAL: In this randomised, double-blind, placebo-controlled trial, 20 subjects suffering from allergic rhinitis because of house dust mite allergens received a single dose of Nasya/Prevalin or saline spray before allergen challenge. Total nasal symptom score and total ocular symptom score were assessed 15, 30, 60, 75, 90, 120 and 240 min after challenge. Further, the appearance of the mucosa was examined by rhinoscopy. RESULTS: A single treatment with Nasya/Prevalin led to a significant reduction of TNSS at 60, 75 and 90 min after dust mite allergen challenge as compared with placebo (p(VCAS) = 0.021, p(VCAS) = 0.035, p(VCAS) = 0.036, respectively). Mucosa changes assessed by the rhinoscopic score (on swelling, secretion and colour) were significantly worse in the placebo group compared with the Nasya/Prevalin group (P = 0.033). Nasya/Prevalin was well tolerated, and the safety was comparable with placebo. CONCLUSIONS: Treatment with Nasya/Prevalin was effective in preventing allergic reactions induced by dust mite allergen challenge. Please cite this paper as: Stoelzel K, Bothe G, Chong PW and Lenarz M. Safety and efficacy of Nasya/Prevalin in reducing symptoms of allergic rhinitis. Clin Respir J 2014; 8: 382–390. |
format | Online Article Text |
id | pubmed-4235399 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BlackWell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-42353992014-12-15 Safety and efficacy of Nasya/Prevalin in reducing symptoms of allergic rhinitis Stoelzel, Katharina Bothe, Gordana Chong, Pee Win Lenarz, Minoo Clin Respir J Original Articles BACKGROUND: Nasya/Prevalin is a natural, drug-free nasal spray for treatment and prevention of allergic rhinitis. Because of its thixotropic property, it forms a barrier on the nasal mucosa, preventing allergen contact. This study assesses the clinical efficacy and safety of Nasya/Prevalin in a nasal provocation test with house dust mite allergens. METHODOLOGY/PRINCIPAL: In this randomised, double-blind, placebo-controlled trial, 20 subjects suffering from allergic rhinitis because of house dust mite allergens received a single dose of Nasya/Prevalin or saline spray before allergen challenge. Total nasal symptom score and total ocular symptom score were assessed 15, 30, 60, 75, 90, 120 and 240 min after challenge. Further, the appearance of the mucosa was examined by rhinoscopy. RESULTS: A single treatment with Nasya/Prevalin led to a significant reduction of TNSS at 60, 75 and 90 min after dust mite allergen challenge as compared with placebo (p(VCAS) = 0.021, p(VCAS) = 0.035, p(VCAS) = 0.036, respectively). Mucosa changes assessed by the rhinoscopic score (on swelling, secretion and colour) were significantly worse in the placebo group compared with the Nasya/Prevalin group (P = 0.033). Nasya/Prevalin was well tolerated, and the safety was comparable with placebo. CONCLUSIONS: Treatment with Nasya/Prevalin was effective in preventing allergic reactions induced by dust mite allergen challenge. Please cite this paper as: Stoelzel K, Bothe G, Chong PW and Lenarz M. Safety and efficacy of Nasya/Prevalin in reducing symptoms of allergic rhinitis. Clin Respir J 2014; 8: 382–390. BlackWell Publishing Ltd 2014-10 2013-12-23 /pmc/articles/PMC4235399/ /pubmed/24279907 http://dx.doi.org/10.1111/crj.12080 Text en © 2013 John Wiley & Sons Ltd http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Stoelzel, Katharina Bothe, Gordana Chong, Pee Win Lenarz, Minoo Safety and efficacy of Nasya/Prevalin in reducing symptoms of allergic rhinitis |
title | Safety and efficacy of Nasya/Prevalin in reducing symptoms of allergic rhinitis |
title_full | Safety and efficacy of Nasya/Prevalin in reducing symptoms of allergic rhinitis |
title_fullStr | Safety and efficacy of Nasya/Prevalin in reducing symptoms of allergic rhinitis |
title_full_unstemmed | Safety and efficacy of Nasya/Prevalin in reducing symptoms of allergic rhinitis |
title_short | Safety and efficacy of Nasya/Prevalin in reducing symptoms of allergic rhinitis |
title_sort | safety and efficacy of nasya/prevalin in reducing symptoms of allergic rhinitis |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235399/ https://www.ncbi.nlm.nih.gov/pubmed/24279907 http://dx.doi.org/10.1111/crj.12080 |
work_keys_str_mv | AT stoelzelkatharina safetyandefficacyofnasyaprevalininreducingsymptomsofallergicrhinitis AT bothegordana safetyandefficacyofnasyaprevalininreducingsymptomsofallergicrhinitis AT chongpeewin safetyandefficacyofnasyaprevalininreducingsymptomsofallergicrhinitis AT lenarzminoo safetyandefficacyofnasyaprevalininreducingsymptomsofallergicrhinitis |